1. Committee on Obstetric Practice. Committee opinion no. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2017; 130: e102–9.
2. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50: 515–25.
3. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; 3: CD004454.
4. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994; 12: 1–24.
5. Magann EF, Haram K, Ounpraseuth S, Mortensen JH, Spencer HJ, Morrison JC. Use of antenatal corticosteroids in special circumstances: a comprehensive review. Acta Obstet Gynecol Scand 2017; 96: 395–409.
7. Melamed N, Pittini A, Barrett J, Shah J, Yoon EW, Lemyre B, et al. Antenatal corticosteroids and outcomes of small-for-gestational-age neonates. Obstet Gynecol 2016; 128: 1001–8.
8. Kim WJ, Han YS, Ko HS, Park IY, Shin JC, Wie JH. Antenatal corticosteroids and outcomes of preterm small-for-gestationalage neonates in a single medical center. Obstet Gynecol Sci 2018; 61: 7–13.
9. Torrance HL, Mulder EJ, Brouwers HA, van Bel F, Visser GH. Respiratory outcome in preterm small for gestational age fetuses with or without abnormal umbilical artery Doppler and/or maternal hypertension. J Matern Fetal Neonatal Med 2007; 20: 613–21.
10. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network. Am J Obstet Gynecol 2000; 182(1 Pt 1): 198–206.
11. van Stralen G, van der Bos J, Lopriore E, Te Pas AB, Bloemenkamp KW, Walther FJ, et al. No short-term benefits of antenatal corticosteroid treatment in severely preterm growth restricted fetuses: a case-control study. Early Hum Dev 2009; 85: 253–7.
12. Schaap AH, Wolf H, Bruinse HW, Smolders-De Haas H, Van Ertbruggen I, Treffers PE. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol 2001; 97: 954–60.
13. Simchen MJ, Alkazaleh F, Adamson SL, Windrim R, Telford J, Beyene J, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004; 190: 296–304.
16. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92: 529–34.
17. Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics 2010; 125: e214–24.
18. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants: 2013 update. Neonatology 2013; 103: 353–68.
19. Economides DL, Nicolaides KH, Linton EA, Perry LA, Chard T. Plasma cortisol and adrenocorticotropin in appropriate and small for gestational age fetuses. Fetal Ther 1988; 3: 158–64.
20. Torrance HL, Derks JB, Scherjon SA, Wijnberger LD, Visser GH. Is antenatal steroid treatment effective in preterm IUGR fetuses? Acta Obstet Gynecol Scand 2009; 88: 1068–73.
22. McTernan CL, Draper N, Nicholson H, Chalder SM, Driver P, Hewison M, et al. Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab 2001; 86: 4979–83.
23. Ozdemir H, Guvenal T, Cetin M, Kaya T, Cetin A. A placebocontrolled comparison of effects of repetitive doses of betamethasone and dexamethasone on lung maturation and lung, liver, and body weights of mouse pups. Pediatr Res 2003; 53: 98–103.
25. Morrison JL, Orgeig S. Antenatal glucocorticoid treatment of the growth-restricted fetus: benefit or cost? Reprod Sci 2009; 16: 527–38.
26. Riskin-Mashiah S, Riskin A, Bader D, Kugelman A, Boyko V, Lerner-Geva L, et al. Antenatal corticosteroid treatment in singleton, small-for-gestational-age infants born at 24-31 weeks' gestation: a population-based study. BJOG 2016; 123: 1779–86.
27. Ting JY, Kingdom JC, Shah PS. Antenatal glucocorticoids, magnesium sulfate, and mode of birth in preterm fetal small for gestational age. Am J Obstet Gynecol 2018; 218(2S): S818–28.
28. McGillick EV, Orgeig S, Williams MT, Morrison JL. Risk of respiratory distress syndrome and efficacy of glucocorticoids: are they the same in the normally grown and growth-restricted infant? Reprod Sci 2016; 23: 1459–72.
29. Elimian A, Figueroa R, Spitzer AR, Ogburn PL, Wiencek V, Quirk JG. Antenatal corticosteroids: are incomplete courses beneficial? Obstet Gynecol 2003; 102: 352–5.
30. Miller SL, Supramaniam VG, Jenkin G, Walker DW, Wallace EM. Cardiovascular responses to maternal betamethasone administration in the intrauterine growth-restricted ovine fetus. Am J Obstet Gynecol 2009; 201: 613. e1-8.
31. Lai MY, Chu SM, Lakshminrusimha S, Lin HC. Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Pediatr Neonatol 2018; 59: 15–23.
32. Mitsiakos G, Kovacs L, Papageorgiou A. Are antenatal steroids beneficial to severely growth restricted fetuses? J Matern Fetal Neonatal Med 2013; 26: 1496–9.